Sugi Predict

Sugi Predict / Compounds / SCHEMBL507119

SCHEMBL507119

SCHEMBL507119

C[C@@H](N)COc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.63
▸ MAOA P21397 2/20 0.62
▸ PTGS1 P23219 1/20 0.62
▸ SCN4A P35499 5/20 0.61
▸ SCN1A P35498 2/20 0.53
▸ SCN5A Q14524 2/20 0.53
▸ SCN9A Q15858 2/20 0.53
▸ CYP2D6 P10635 2/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ TSHR P16473 1/20 0.53
▸ NFKB1 P19838 1/20 0.53
▸ KCNK3 O14649 1/20 0.53
▸ CACNA1F O60840 1/20 0.53
▸ KCNK2 O95069 1/20 0.53
▸ GBA1 P04062 1/20 0.53
▸ HTR2A P28223 1/20 0.53
▸ SLC6A4 P31645 1/20 0.53
▸ HTR2B P41595 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL366154 1.00 LMNA (0.63) LMNAMAOAPTGS1SCN4ASCN1A
SCHEMBL4442204 1.00 LMNA (0.63) LMNAMAOAPTGS1SCN4ASCN1A
Hydrochloric Acid SCHEMBL21315607 0.98 LMNA (0.61) LMNAMAOAPTGS1SCN4ASCN1A
Hydrochloric Acid SCHEMBL19668691 0.98 LMNA (0.61) LMNAMAOAPTGS1SCN4ASCN1A
Hydrochloric Acid SCHEMBL28934580 0.98 LMNA (0.61) LMNAMAOAPTGS1SCN4ASCN1A
Ammonia Solution, Strong SCHEMBL9819193 0.98 LMNA (0.61) LMNAMAOAPTGS1SCN4ASCN1A
SCHEMBL17947648 0.88 MAOA (0.50) LMNAMAOAPTGS1SCN4ASCN1A
Tetradecane SCHEMBL29054435 0.87 MAOA (0.50) LMNAMAOAPTGS1SCN4ASCN1A
SCHEMBL10606913 0.85 MAOB (0.59) LMNAMAOAPTGS1CYP1A2
SCHEMBL9053577 0.84 SCN4A (0.57) LMNAMAOASCN4ASCN1ASCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100197914-A1 Purine Derivatives as Adenosine Al Receptor Ligands NOVARTIS AG (CH) 2010-08-05 — — US claimed
EP-2205601-A1 PURINE DERIVATIVES AS ADENOSINE AL RECEPTOR LIGANDS Novartis Ag (CH) 2010-07-14 — — EP claimed
WO-2009050199-A1 PURINE DERIVATIVES AS ADENOSINE AL RECEPTOR LIGANDS NOVARTIS AG (CH) 2009-04-23 — — WO claimed
CN-119020446-A Process for preparing chiral aryl amines, heteroaryl amines and alkyl amines 河北工业大学 2024-11-26 — — CN disclosed
CN-113846069-B Amphetamine dehydrogenase mutant and application thereof in chiral amine synthesis 华东理工大学 2023-06-27 — — CN disclosed
US-20190270696-A1 COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2019-09-05 — — US disclosed
US-10023886-B2 (R)-selective amination PATHEON HOLDINGS I B.V. (NL) 2018-07-17 — — US disclosed
WO-2017210371-A2 COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2017-12-07 — — WO disclosed
EP-2593556-B1 ENZYMATIC METHOD FOR (R)-SELECTIVE AMINATION DPX HOLDINGS BV (NL) 2017-08-30 — — EP disclosed
US-20160032335-A1 (R)- SELECTIVE AMINATION DPX HOLDINGS B.V. (NL) 2016-02-04 — — US disclosed
EP-1720836-B1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS LILLY CO ELI (US) 2014-04-16 — — EP disclosed
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ARRAY BIOPHARMA, INC. 2009-04-16 — — US disclosed
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ARRAY BIOPHARMA, INC. 2009-04-16 — — US disclosed
CN-1934088-A As 5-HT2c6-substituted 2,3,4, 5-tetrahydro-1H-benzo [ d ] receptor agonists]Aza * LILLY CO ELI (US) 2007-03-21 — — CN disclosed
US-20040106653-A1 Aminoalcohol derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-03 — — US disclosed
WO-2004045610-A1 AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS FUJISAWA PHARMACEUTICAL CO., LTD (JP) 2004-06-03 — — WO disclosed
US-5672588-A Purine derivatives NOVO NORDISK A/S (DK) 1997-09-30 — — US disclosed
EP-0603348-A1 PURINE DERIVATIVES NOVO NORDISK A/S (DK) 1994-06-29 — — EP disclosed
US-5300437-A Using omega-amino acid transaminase CELGENE CORPORATION (US) 1994-04-05 — — US disclosed
WO-1993023418-A1 PURINE DERIVATIVES NOVO NORDISK A/S (DK) 1993-11-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS HTR2C, HTR5A, HTR4 LMNA 4504/4885MAOA 462/4885PTGS1 3434/4885
US-20100197914-A1 Purine Derivatives as Adenosine Al Receptor Ligands ADORA2A, ADORA1, ADORA3 LMNA 2449/4885MAOA 585/4885PTGS1 1327/4885
US-20190270696-A1 COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS SCN1B, CACNA1E, SCN2B LMNA 1789/4885MAOA 1676/4885PTGS1 898/4885
US-20040106653-A1 Aminoalcohol derivatives FANCD2, FANCI, HRH2 LMNA 3890/4885MAOA 3774/4885PTGS1 1789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.